Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Florence DelestrePierre CharlesAlexandre KarrasChristian PagnouxAntoine NéelPascal CohenOlivier AumaîtreStanislas FaguerPierre GobertFrançois MaurierMaxime SamsonPascal GodmerBernard BonnotteVincent CottinCatherine Hanrotel-SaliouThomas Le GallouPierre-Louis CarronHélène Desmurs-ClavelGuillaume DirezNoémie Jourde-ChicheFrancois LifermannNicolas Martin-SilvaGrégory PugnetThomas QuéméneurMarie MatignonYgal BenhamouEric DaugasEstibaliz LazaroNicolas LimalMaïzé DucretAntoine HuartJean-François ViallardEric HachullaElodie PerrodeauXavier PuechalLoïc GuillevinRaphaël PorcherBenjamin Terriernull nullPublished in: Annals of the rheumatic diseases (2023)
According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.